SCHEMBL3010733

SCHEMBL3010733

Cc1ccc(S(=O)(=O)N2CCN(c3nc(Cc4ccc(Cl)cc4)cs3)CC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
HTT P42858 2/20 0.48
KDM4E B2RXH2 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
LSS P48449 2/20 0.46
HSD11B1 P28845 1/20 0.46
POLB P06746 1/20 0.45
ABL1 P00519 1/20 0.45
BCR P11274 1/20 0.45
PKM P14618 3/20 0.45
LMNA P02545 2/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 2/20 0.44
RXFP1 Q9HBX9 1/20 0.44
GBA1 P04062 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006852 1.00 ALDH1A1 (0.48) ALDH1A1HTTKDM4ENPSR1SMN1; SMN2
SCHEMBL3012775 0.95 MEN1 (0.51) ALDH1A1HTTSMN1; SMN2L3MBTL1MEN1
SCHEMBL3007797 0.95 SMN1; SMN2 (0.51) ALDH1A1HTTKDM4ENPSR1SMN1; SMN2
SCHEMBL3018595 0.92 THRB (0.51) ALDH1A1KDM4ENPSR1SMN1; SMN2L3MBTL1
SCHEMBL3018162 0.91 ALDH1A1 (0.42) ALDH1A1HTTKDM4ENPSR1SMN1; SMN2
SCHEMBL3015126 0.91 POLB (0.47) ALDH1A1HTTKDM4ENPSR1SMN1; SMN2
SCHEMBL3012502 0.91 ALDH1A1 (0.47) ALDH1A1HTTKDM4ENPSR1SMN1; SMN2
SCHEMBL3000163 0.91 SMN1; SMN2 (0.47) ALDH1A1HTTSMN1; SMN2L3MBTL1MEN1
SCHEMBL3008698 0.90 POLB (0.46) ALDH1A1KDM4ENPSR1SMN1; SMN2L3MBTL1
SCHEMBL3017901 0.90 THRB (0.47) ALDH1A1HTTKDM4ENPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885HTT 2/4885KDM4E 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.